Table 1.
Baseline Demographics and Clinical Data1
| Complete Response Group (n=5) |
No Response Group (n=4) |
P (CR v NR) | |
|---|---|---|---|
| Age (years, ±SD) | 24.8±4.97 | 30±8.16 | 0.2 |
| Female (%) | 4 (80) | 4 (100) | 1.0 |
| LN Class at Flare (% Class IV) | 3 (60) | 4 (100) | 0.4 |
| First LN Flare (%) | 60% | 25% | 0.4 |
| Induction Therapy CYC (%) | 2 (40) | 2 (50) | 1.0 |
| Induction Therapy MMF (%) | 3 (60) | 2 (50) | 0.8 |
| SCr2 at B×13 (±SD) | 0.94±0.31 | 1.08±0.28 | 0.7 |
| SCr at B×24 (±SD) | 0.74±0.15 | 1.18±0.36 | 0.004 |
| Proteinuria5 at B×1 (±SD) | 3.04±1.11 | 5.5±2.08 | 0.014 |
| Proteinuria at B×2 (±SD) | 0.24±0.09 | 3.33±1.27 | <0.0001 |
| Activity Index at B×1 (range) | 6(4-8) | 5 (4-12) | 0.1 |
| Chronicity Index at B×1 (range) | 2 (0-4) | 5 (0-6) | 0.3 |
| Activity Index at B×2 (range) | 3 (0-8) | 3.5 (0-9) | 0.7 |
| Chronicity Index at B×2 (range) | 4(0-5) | 5 (4-6) | 0.1 |
1
p-value calculation: Fisher’s exact test was applied to categorical demographic and clinical parameters: Age, sex, LN Class, and induction therapy. ANOVA was used to look for significant trends among all groups, and t-tests were used to compare differences between two specific groups
2
Serum creatinine in mg/dl
3
Biopsy 1 (B×1), done at LN flare
4
Biopsy 2 (B×2), done after completion of induction therapy
5
24-hour Urine protein in g/d